Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

CREMOLINI, CHIARA; MORANO, FRANCESCO; MORETTO, ROBERTO; Berenato, R; Tamborini, E; Perrone, F; ROSSINI, DANIELE; Gloghini, A; Busico, A; ZUCCHELLI, GEMMA; Baratelli, C; Tamburini, E; Tampellini, M; SENSI, ELISA; Fucà, G; Volpi, C; Milione, M; Di Maio, M; FONTANINI, GABRIELLA; De Braud, F; FALCONE, ALFREDO; Pietrantonio, F.

research article

oai:arpi.unipi.it:11568/876999

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

Authors: CHIARA CREMOLINI
FRANCESCO MORANO
ROBERTO MORETTO
R Berenato
E Tamborini
F Perrone
DANIELE ROSSINI
A Gloghini
A Busico
GEMMA ZUCCHELLI
C Baratelli
E Tamburini
M Tampellini
ELISA SENSI
G Fucà
C Volpi
M Milione
M Di Maio
GABRIELLA FONTANINI
F De Braud
ALFREDO FALCONE
F. Pietrantonio
Publication date: 1 January 2017
Publisher
Doi

Abstract

Refining the selection of metastatic colorectal cancer (mCRC) patients candidates for anti-EGFR monoclonal antibodies beyond RAS and BRAF testing is a challenge of precision oncology. Several uncommon genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than EGFR or downstream signaling pathways, have been suggested by preclinical and retrospective studies

Similar works

Full text

Open in the Core reader

Download PDF

Archivio della Ricerca - Università di Pisa

oai:arpi.unipi.it:11568/876999

Last time updated on 03/12/2017

This paper was published in Archivio della Ricerca - Università di Pisa.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.